Plain-English translation of NCT07392658 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This is a Phase II trial testing , a newer injectable medication, combined with standard chemotherapy in patients with advanced lung cancer that has a specific genetic mutation (EGFR exon20 insertion). The study is designed for patients whose kidney function or other health factors make standard platinum-based chemotherapy unsafe. Researchers want to see if this combination is effective and safe for treating this particular type of lung cancer.
Many people with this specific type of advanced lung cancer cannot receive the traditional first-line treatment because of kidney problems, age, or other medical conditions. This trial explores whether this medication offers a better option for those patients who are not candidates for standard chemotherapy.
You likely qualify if…
You likely don't qualify if…
You would receive the medication as an injection under the skin on specific days (Days 1, 8, and 15 of your first cycle, then every 3 weeks after that), combined with one of two standard chemotherapy medications (pemetrexed or gemcitabine) that your doctor chooses. You will continue treatment until your cancer progresses, side effects become unacceptable, or you decide to stop. Every 8 weeks, you'll have imaging scans to check how well the treatment is working, and your doctor will monitor you regularly for side effects using standard safety assessments.
AI-generated summary from trial data · Jun 18, 2026 · Not medical advice
Italy